Zacks Research Brokers Boost Earnings Estimates for Cencora

Cencora, Inc. (NYSE:COR) – Investment analysts at Zacks Research raised their Q1 2025 earnings per share estimates for shares of Cencora in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings of $3.42 per share for the quarter, up from their previous estimate of $3.28. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Zacks Research also issued estimates for Cencora’s Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.82 EPS, Q3 2026 earnings at $3.85 EPS, Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $16.17 EPS and FY2027 earnings at $17.41 EPS.

Several other research analysts have also recently weighed in on the company. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Barclays upped their price objective on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Evercore ISI upped their price objective on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Trading Up 0.1 %

Shares of Cencora stock opened at $250.05 on Monday. The stock has a market cap of $49.27 billion, a P/E ratio of 33.30, a P/E/G ratio of 1.66 and a beta of 0.45. The stock’s 50 day simple moving average is $235.84 and its 200-day simple moving average is $233.00. Cencora has a 1-year low of $195.83 and a 1-year high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Hedge Funds Weigh In On Cencora

Large investors have recently bought and sold shares of the business. New Millennium Group LLC purchased a new position in Cencora in the second quarter valued at about $26,000. MFA Wealth Advisors LLC purchased a new position in Cencora in the second quarter valued at about $30,000. Concord Wealth Partners purchased a new position in Cencora in the third quarter valued at about $30,000. SYSTM Wealth Solutions LLC purchased a new position in Cencora in the second quarter valued at about $36,000. Finally, Ashton Thomas Securities LLC purchased a new position in Cencora in the third quarter valued at about $41,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company’s stock, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have sold 93,018 shares of company stock valued at $22,478,942 over the last quarter. 15.80% of the stock is owned by insiders.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.